Results 291 to 300 of about 1,467,646 (404)

Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex [PDF]

, 2011
Keyur Gada
openalex   +1 more source

Dynamical analysis of antibody aggregation in the CHO cell culture with Thermo Responsive Protein A (TRPA) column [PDF]

, 2013

core   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, Volume 19, Issue 7, Page 1979-1997, July 2025.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. [PDF]

Cancer Immunol Immunother
Wang Y, Pan S, Tian J, Wang J, Yu Y, Wang S, Li F, Yang L, Liu X, Shen Y, Qiu Q, Luan J, Jia M, Xiong C, Duan X, Wang FS, Meng F.   +16 more
europepmc   +1 more source

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas [PDF]

, 2012
Pankaj Gupta, David M. Goldenberg, Edmund A. Rossi, Thomas M. Cardillo, John C. Byrd, Natarajan Muthusamy, Richard R. Furman, Chien‐Hsing Chang   +7 more
openalex   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, Volume 19, Issue 7, Page 1998-2013, July 2025.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities. [PDF]

Protein Sci
Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rödel JM, Scheller J, Pudewell S, Floss DM, Krah S, Harwardt J, Doerner A, Helming L, Xu C, Menrad A, Evers A, Kolmar H, Elter D, Pekar L, Zielonka S.   +19 more
europepmc   +1 more source

A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2–Expressing Epithelial Cancers [PDF]

, 2012
Robert M. Sharkey, Catharina M. van Rij, Habibe Karacay, Edmund A. Rossi, Cathelijne Frielink, Celeste A.S. Regino, Thomas M. Cardillo, William J. McBride, Chien‐Hsing Chang, Otto C. Boerman, David M. Goldenberg   +10 more
openalex   +1 more source

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

Advanced Science, Volume 12, Issue 25, July 3, 2025.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang, Xinyu Qiu, Xiaoning Tong, Shaoju Gan, Weicheng Yi, Sitao Xie, Xiangsheng Liu, Chao Zuo, Weihong Tan   +8 more
wiley   +1 more source

Anti‐CD3 × anti‐GD2 bispecific antibody redirects T‐cell cytolytic activity to neuroblastoma targets [PDF]

, 2012
Maxim Yankelevich, Sri Vidya Kondadasula, Archana Thakur, Steven Buck, Nai‐Kong V. Cheung, Lawrence G. Lum   +5 more
openalex   +1 more source